ROCK2 Inhibitor for CCM/Orphan CNS
Cerebral Cavernous Malformations (CCMs) and orphan CNS diseases
Phase 2Active
Key Facts
Indication
Cerebral Cavernous Malformations (CCMs) and orphan CNS diseases
Phase
Phase 2
Status
Active
Company
About Graviton Bioscience
Graviton Bioscience, founded in 2018 and based in New York, is a private, clinical-stage biotech developing a portfolio of selective ROCK2 inhibitors. The company's platform targets the restoration of biological equilibrium to treat a range of fibrotic, autoimmune, and CNS disorders. It has advanced its lead programs into clinical development, supported by strategic partnerships with Ovid Therapeutics, Sino Biopharmaceutical, and an equity investment from Sanofi.
View full company profile